Entry Point Capital, LLC Recursion Pharmaceuticals, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RXRX
# of Institutions
285Shares Held
236MCall Options Held
972KPut Options Held
2.4M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl28.1MShares$185 Million1.92% of portfolio
-
Baillie Gifford & CO26.6MShares$175 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$142 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$114 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$101 Million1.74% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.19B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...